The abstract is read at the publisher; the summary is JClub's.
IgM antibodies against oxidized LDL phospholipids are linked to lower cardiovascular risk by neutralizing modified LDL and promoting its clearance, highlighting atherosclerosis-relevant immune protection.
- Why it matters: Antioxidant trials have failed to reduce cardiovascular risk, leaving uncertainty about LDL oxidation as a therapeutic target and motivating antibody-based strategies instead.
- What they did: Evidence from observational associations and mechanistic studies shows IgM antibodies neutralize and enhance clearance of modified LDL, while IgG against aldehyde-modified apolipoprotein B-100 peptides forms local immune complexes that dampen inflammatory plaque macrophage activity.
- The result: A phase 2 pilot study found orticumab reduced an imaging index of local coronary arterial inflammation in patients with psoriasis, supporting further development of oxidized LDL antibodies to limit atherothrombotic disease.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.